Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration

Inhibition of vascular endothelial growth factor (VEGF) is the standard therapy for neovascular age-related macular degeneration (nAMD). However, anti-VEGF agents used in the clinic require repeated injections, causing adverse effects. Gene therapy could provide sustained anti-VEGF levels after a si...

Descripción completa

Detalles Bibliográficos
Autores principales: She, Kaiqin, Su, Jing, Wang, Qingnan, Liu, Yi, Zhong, Xiaomei, Jin, Xiu, Zhao, Qinyu, Xiao, Jianlu, Li, Ruiting, Deng, Hongxin, Lu, Fang, Yang, Yang, Wei, Yuquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800040/
https://www.ncbi.nlm.nih.gov/pubmed/35141350
http://dx.doi.org/10.1016/j.omtm.2022.01.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800040/
https://www.ncbi.nlm.nih.gov/pubmed/35141350
http://dx.doi.org/10.1016/j.omtm.2022.01.002

Ejemplares similares